SCHEMBL6286243

SCHEMBL6286243

CC(=NNC(=N)N)c1cn(S(=O)(=O)c2cccc3c(N(C)C)cccc23)c2ccccc12

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
F2 P00734 3/20 0.46
PRSS1 P07477 3/20 0.46
PRSS2 P07478 3/20 0.46
PRSS3 P35030 3/20 0.46
KMT2A Q03164 2/20 0.41
ATM Q13315 1/20 0.41
CA2 P00918 1/20 0.40
FABP4 P15090 2/20 0.40
HTR6 P50406 6/20 0.39
LMNA P02545 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
PLK1 P53350 1/20 0.37
MEN1 O00255 1/20 0.37
KDM4E B2RXH2 1/20 0.36
NSD2 O96028 1/20 0.36
TSHR P16473 1/20 0.36
HSD17B10 Q99714 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6286239 1.00 F2 (0.46) F2PRSS1PRSS2PRSS3KMT2A
SCHEMBL6287562 0.88 HTR6 (0.46) F2PRSS1PRSS2PRSS3KMT2A
SCHEMBL6287560 0.88 HTR6 (0.46) F2PRSS1PRSS2PRSS3KMT2A
SCHEMBL6286325 0.83 HTR6 (0.48) KMT2AFABP4HTR6LMNASMN1; SMN2
SCHEMBL6286328 0.83 HTR6 (0.48) KMT2AFABP4HTR6LMNASMN1; SMN2
SCHEMBL6286909 0.81 LMNA (0.60) KMT2ACA2HTR6LMNASMN1; SMN2
SCHEMBL6286906 0.81 LMNA (0.60) KMT2ACA2HTR6LMNASMN1; SMN2
SCHEMBL31202643 0.81 LMNA (0.60) F2PRSS1PRSS2PRSS3KMT2A
SCHEMBL6286249 0.80 CA2 (0.44) F2PRSS1PRSS2PRSS3KMT2A
SCHEMBL6286245 0.80 CA2 (0.44) F2PRSS1PRSS2PRSS3KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6906095-B2 Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands WYETH (US) 2005-06-14 US claimed
US-20040002527-A1 Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands WYETH 2004-01-01 US claimed
US-6906095-B2 Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands WYETH (US) 2005-06-14 US disclosed
US-20040002527-A1 Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands WYETH 2004-01-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002527-A1 Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands HTR6, HTR5A, HTR2A F2 4141/4885PRSS1 2793/4885PRSS2 2757/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.